Management of patients and side effects during cyclosporine therapy for cutaneous disorders

Journal of the American Academy of Dermatology

Volumn 23, Issue 6, 1990, Pages 1265-1275

  Fradin, Mark S ^a   Ellis, Charles N ^a   Voorhees, John J ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; LIPID;

ADVERSE DRUG REACTION; CANCER RISK; CONFERENCE PAPER; HUMAN; HYPERTENSION; INFECTION; NEPHROTOXICITY; NEUROTOXICITY; PRIORITY JOURNAL; SIDE EFFECT; SKIN DISEASE;

CYCLOSPORINS; HUMAN; SKIN DISEASES; SUPPORT, NON-U.S. GOV'T;

EID: 0025651827     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/0190-9622(90)70353-J     Document Type: Article

References (126)

1. Cyclosporine in autoimmune diseases
2. Cyclosporine A: a review of its dermatologie applications
3. Cyclosponne improves psoriasis in a double-blind study
4. Clearance of psoriasis with low dose cyclosporin
5. Treatment of resistant severe psoriasis with systemic cyclosporine
6. Generalized pustular psoriasis (von Zumbusch) responding to cyclosporine A
7. Cyclosporin A in acrodermatitis continua
8. Cyclosporin in the treatment of palmo-plantar pustulosis
9. Low dose cyclosporine improves psoriasis: a double-blind study [Abstract]
10. Cyclosporine A—induced hair growth in human renal allograft recipients and alopecia areata
11. Cyclosporine A in the treatment of severe alopecia areata
12. Treatment of severe alopecia areata by topical applications of cyclosporine: comparative trial versus placebo in 43 patients
13. Oral cyclosporine for the treatment of alopecia areata
14. Pyoderma gangrenosum treated with cyclosporine A
15. Cyclosporine therapy for pyoderma gangrenosum associated with sclerosing cholangitis and ulcerative colitis
16. Pyoderma gangrenosum: response to cyclosporin A
17. Effectiveness of cyclosporin therapy for Behçet's disease
18. Evaluation of conventional therapy versus cyclosporine A in Behçet's syndrome
19. Efficacy of low dose cyclosporine in severe atopic skin disease
20. Cyclosporine therapy for severe atopic dermatitis
21. A preliminary open study of topical cyclosporin for hypertrophic lichen planus
22. Treatment of severe lichen planus with cyclosporine
23. Cyclosporin A for the treatment of severe lichen planus
24. Effects of cyclosporine on bullous pemphigoid and pemphigus
25. Cyclosporine: new immunosuppressive agent in bullous pemphigoid and pemphigus
26. Cyclosporine A for the treatment of systemic lupus erythematosus
27. Effects of cyclosporine in severe systemic lupus erythematosus
28. Combined cyclosporin-steroid treatment of systemic lupus erythematosus
29. Cyclosporine for polymyositis
30. Cyclosporine for polymyositis [Letter]
31. Cyclosporine as monotherapy for polymyositis?
32. Clearing of epidermolysis bullosa acquisita with cyclosporine
33. Clearing of epidermolysis bullosa acquisita with cyclosporine [Letter]
34. Use of cyclosporine in psoriasis
35. Cyclosporine
36. Effect of erythromycin on cyclosporine levels
37. Norfloxacin-cyclosporine interaction
38. Pharmacodynamics of cyclosporin-ketoconazole interaction in mice
39. Time course of cyclosporin-itraconazole interaction
40. Cyclosporine and ketoconazole
41. Clinical pharmacokinetics of cyclosporin
42. Oral contraceptive interactions with cyclosporin
43. Toxicity of cyclosporine during treatment with androgens
44. Cyclosporin interacting with danazol and norethisterone
45. High dose methylprednisolone increases plasma cyclosporin levels in renal transplant recipients
46. Effect of Cimetidine on microsomal drug metabolism in man
47. Cyclosporine-cimetidine interaction
48. Interaction of cyclosporine and calcium antagonists
49. Cyclosporine-diltiazemjnteraction
50. Nicardipine increases cyclosporine blood levels
51. Verapamil inhibits cyclosporin metabolism
52. Evaluation of cyclosporine-phenytoin interaction with observations on cyclosporine metabolites
53. Interaction between phenytoin and cyclosporinefollowing organ transplantation
54. Interaction between cyclosporine A and phenybarbitone
55. Cyclosporine and tegretol—another drug interaction
56. Acute rejection and massive cyclosporine requirements in heart transplant recipients treated with rifampin
57. Cyclosporine and intravenous sulphadimidine and trimethoprim
58. Cyclosporine treatment for rheumatoid arthritis: a placebo-controlled double blind multicentre study
59. Enhancement of high dose cyclosporin A toxicity by frusemide
60. Enhancement of cyclosporin nephrotoxicity by diuretic therapy
61. Severe nephrotoxicity caused by the combined use of gentamicin and cyclosporine in renal allograft recipients
62. Renal and hepatic function in rats treated with cyclosporine A in combination with gentamicin or cephalosporin antibiotics
63. Cyclosporine interaction with ketoconazole and melphalan
64. Acute renal toxicity with combined use of amphotericin B and cyclosporine after marrow transplantation
65. Nephrotoxicity of trimethoprim and cotrimoxazole in renal allograft recipients treated with cyclosporine
66. Digoxin-cyclospcrine interaction: severe digitalis toxicity after cyclosporine treatment
67. Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation
68. Cyclosporine therapy for psoriasis: serum creatinine measurements are an unreliable predictor of decreased renal function
69. Limitations of creatinine in quantifying the severity of cyclosporine-induced chronic nephrotoxicity
70. Cyclosporin A administration in dermatology: once a day or in fractional doses?
71. Cyclosporine A administration: once a day or in fractional doses?
72. New onset of hypertension following cardiac transplantation: a prelirninary report and analysis
73. Nephrotoxicity and hypertension in patients with autoimmune diseases treated with Ciclosporin
74. Long term cyclosporine in the management of psoriasis
75. Cyclosporine maintenance therapy in psoriasis
76. Cyclosporine A-calcium channels interaction: a possible mechanism for nephrotoxicity
77. In vitro cyclosporine toxicity: the effect of verapamil
78. Long-term effects of cyclosporine on renal function in organ transplant recipients
79. Cyclosporine-associated hypertension
80. Hypertension in cyclosporine-treated renal transplant recipients is sodium dependent
81. Hypertension and convulsions in children receiving cyclosporin A [Letter]
82. Correlation of hypomagnesemia with the onset of cyclosporine-associated hypertension in marrow transplant patients
83. Cyclosporin A, methylprednisolone, and convulsions
84. CNS toxicity after liver transplantation
85. Cyclosporine-associated central nervous system toxicity
86. Cyclosporine A hepatotoxicity in 66 renal allograft recipients
87. Cyclosporine associated hepatotoxicity after allogenic marrow transplantation in man
88. Clinical and experimental studies using cyclosporine in renal transplantation
89. Complications in long-term survivors of cardiac transplantation
90. Lipid abnormalities in renal transplant recipients treated with cyclosporine
91. Effects of cyclosporine therapy on plasma lipoprotein levels
92. Alterations in lipid and carbohydrate metabolism attributable to cyclosporin A in renal transplant recipients
93. The effect of food and cholestyramine on the absorption of cyclosporine in cardiac transplant recipients
94. Effect of cyclosporine on plasma lipids and modification with dietary fish oil
95. Fish oil vehicle for cyclosporine lowers renal thromboxanes and reduces experimental nephrotoxicity
96. Fish oil and renal function in cyclosporin-treated psoriasis patients
97. Does fish oil protect renal function in cyclosporin-treated psoriasis patients?
98. Clinical and pharmacological correlations in cyclosporine-induced gingival hyperplasia
99. Light and electron microscopic study of cyclosporine A-induced gingival hyperplasia
100. Myopathy as a possible side-effect of cyclosporin
101. Reversible cyclosporin study myopathy
102. Gout and hyperuricemia in patients on cyclosporin and diuretics
103. Cyclosporin, uric acid, and the kidney
104. The incidence of gout in renal transplant recipients
105. Cyclosporine-induced hyperuricemia and gout
106. Gout in the heart transplant recipient: physiological puzzle and therapeutic challenge
107. Cyclosporine-A in vivo produces severe osteopenia in the rat: effect of dose and duration of administration
108. The effect of cyclosporine A administration and its withdrawal on bone mineral metabolism in the rat
109. Lymphocytes, macrophages and the regulation of bone remodeling
110. Hypertrichosis in patients receiving cyclosporine therapy
111. Does cyclosporine A influence sex hormone level?
112. Assessment of the risks of malignancy and lymphomas developing in patients using Sandimmune
113. Lymphomas and lymphoproliferative lesions under cyclosporine therapy [Letter]
114. Rapid occurrence of nodular cutaneous T-lymphocytic infiltrates with cyclosporine therapy
115. High cumulative dose of ultraviolet radiation is a contraindication for cyclosporin therapy
116. Two distinct squamous cell carcinomas in a psoriasis patient receiving low-dose cyclosporine maintenance treatment
117. Absence of genotoxic potential for cyclosporine in experimental systems
118. Present experience of Sandimmune in pregnancy
119. Thromboembolic complications and hemostatic changes in cyclosporinetreated cadaveric kidney allograft recipients
120. No association between post-transplant erythrocytosis, thromboembolic events, and cyclosporine therapy
121. A single institution, randomized, prospective trial of cyclosporine versus azathioprine-ALG for immunosuppression in renal allograft recipients
122. A randomised clinical trial of cyclosporin in cadaveric renal transplantation
123. Side effects of systemic cyclosporine in patients not undergoing transplantation
124. Action and toxicity of cyclosporine
125. Complications of cyclosporine therapy